Presentations
4Q 2022 Financial Results & Business Update
Feb 22, 2023
J.P. Morgan Healthcare Conference Presentation
Jan 10, 2023
Binding and Signal Profiling of Full and Partial M4 Agonists
Nov 13, 2022
Efficacy of Subtype-Selective, Full vs Partial M4 Muscarinic Receptor Agonists in Modulating Amphetamine-Induced Brain Activity Assessed by Functional MRI (fMRI) in Rats
Nov 13, 2022
Efficacy of CV-0000042, a Novel M4 Receptor Full Agonist, and CV-0000071, a Novel M4 Receptor Partial Agonist, in Preclinical In Vivo Models of Psychosis
Nov 13, 2022
3Q 2022 Financial Results & Business Update
Nov 08, 2022
Cerevel Corporate Presentation - September
Sep 09, 2022
2Q 2022 Financial Results & Business Update
Aug 01, 2022
IARPD 2022 Poster - Setting the TEMPO: A Phase 3 Program to Investigate Tavapadon, a Selective D1/D5 Partial Agonist, for Parkinson’s Disease
May 13, 2022
1Q 2022 Financial Results & Business Update
May 10, 2022